Bolstering your armamentarium with SGLT2 inhibitors.
Sodium-glucose cotransporter-2 inhibitors have a unique mechanism of action in the kidneys that causes glucosuria, which lowers plasma glucose. They are also associated with reduced body weight, BP, and a low incidence of hypoglycemia. The pharmacologic profiles/clinical implications of canagliflozin, dapagliflozin, and empagliflozin are discussed in this article.